
'Free for all': Advocates call for e-scooter regulations as injury numbers climb
Latest data from the Canadian Institute for Health Information (CIHI) said that nearly 1,000 people were hospitalized nationally for scooter-related injuries during the 12-month period starting April 1, 2023. That's up from 810 during the same period of 2022-23.
Half of the injuries — 498 — were related to motorized e-scooters, an increase of 32 per cent over the 375 hospitalizations recorded in 2022-23.
In the same time period Manitoba saw the rise in the total number of injuries jump by 50 per cent.
"I get scared for them because, between a car and a scooter, who's going to win?" said cyclist Marian Siemens, who almost got into an accident earlier this summer because a e-scooter rider ignored a red light.
"He was not paying any attention to the traffic. He could have got smacked … then what would have happened?"
She believes regulations would help curb dangerous driving.
"If they don't follow the rules of the road, they should be fined," she said.
Pamela Fuselli, the CEO of Parachute, a national organization focused on injury-prevention across many fields — at home, on the road, and through activities — said e-scooters are a great low-cost transportation options but they are not toys.
"The injuries can go from cuts and bruises from falling off the e-scooter to broken bones and serious head injuries," she said. "Kids under 16 really shouldn't operate these scooters."
Currently in Manitoba, e-scooters are unregulated which means anyone, at any age, can drive the motorized scooter on streets, sidewalks, and bike paths going any speed.
"I'm just aware of my surroundings and I pick where I drive. I just want to make sure I'm protected if something happens," said Edward Fortier, who uses a scooter to get around the city and commute to work.
"I do know a few people who have had pretty bad accidents on e-scooters, so that's in the back of my mind."
He avoids streets with heavy traffic and plans his route around residential areas or roads that have bike paths he can use.
He says some e-scooter users drive recklessly on the road, making things unsafe for pedestrians, cyclists, and cars.
"If I'm on a sidewalk and there's people … I'm not going to go full speed if there's people walking."
'Not a policy priority'
Rob Kristjansson wants to see motorized e-scooters regulated in Manitoba, much like an electric bike.
"I call it a legal grey area," said Kristjansson, who has been advocating for regulations for years and is a moderator of the e-scooter Winnipeg Facebook group.
According to the City of Winnipeg, motorized vehicles fall under the Highway Traffic Act, which means regulations fall under provincial legislation.
But Kristjansson says amendments made to the act in 2022 give municipalities the power to create bylaws that would set speed limits on shared roads.
The city looked into regulations when there was strong interest in creating scooter-sharing programs, but once that interest died down so did the city's.
Kristjansson has advocated for regulations around speed, age, and where e-scooters can be driven but says he continues to hear the same message from his city councillor: "It is not a policy priority for me in this term."
"I appreciate that the city has many priorities,I just want my thing on the list," he said.
Until motorized scooters are formally recognized in the province, people will continue getting hurt, Kristjansson saod, adding it's a small step with positive impacts down the line.
"To empower regulatory authorities to say 'hey, what you're doing is unsafe, you need to behave like a cyclist' instead of this free for all."
A provincial spokesperson told CBC, "as the use of e-scooters continues to grow, the Manitoba government is actively exploring options to establish a regulatory framework to guide their safe and responsible use across the province."
Amid rising injury rates, advocates call for e-scooter regulations in Manitoba
2 hours ago
It's becoming a popular way to get around, but with the increase of electric scooters on the road, hospitalizations because of them are increasing and some are blaming the lack of rules around their use.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

National Post
7 hours ago
- National Post
Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops
Article content Phase 3 data show Bausch + Lomb's LUMIFY Preservative Free eye drops are as safe and effective as the original LUMIFY in reducing ocular redness The multicenter study with 380 participants confirmed that LUMIFY Preservative Free eye drops are non-inferior in efficacy to the original LUMIFY and have a favorable safety profile, offering an effective preservative-free option for sensitive eyes LUMIFY delivers noticeable results in one minute, lasts up to eight hours and is the No. 1 doctor-recommended redness reliever brand; more info at Article content VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Ophthalmology and Therapy has published results from a phase 3 study which assessed the efficacy and safety of LUMIFY Preservative Free redness reliever eye drops compared to LUMIFY redness reliever eye drops for reducing ocular redness. Article content 'Since launching in 2018, LUMIFY has been the No. 1 doctor-recommended redness reliever brand, known for delivering noticeable results in one minute and lasting up to eight hours,' 1 said John Ferris, president, Consumer, Bausch + Lomb. 'This study demonstrates that our new LUMIFY Preservative Free eye drops reduce redness quickly and are just as safe and effective as the original LUMIFY, providing a needed option for patients with eye sensitivities.' Article content In the randomized, active-controlled, multicenter study, 380 participants with ocular redness received either LUMIFY Preservative Free or LUMIFY, administered as a single drop four times daily for four weeks. The primary objective was to demonstrate that LUMIFY Preservative Free is non-inferior to LUMIFY in reducing ocular redness. The primary efficacy endpoint was investigator-assessed ocular redness score at eight timepoints from five-minutes to 240-minutes after drop administration on day one. The secondary objective of the study was to compare the safety of LUMIFY Preservative Free and LUMIFY. Article content The study met its primary objective, confirming that LUMIFY Preservative Free is statistically non-inferior to LUMIFY in reducing ocular redness in adults. A day one analysis of all 11 time points (one minute to 480 minutes post-administration) further supported these findings; and additional secondary efficacy endpoint data from one minute, 360 minutes and 480 minutes post-administration demonstrated that LUMIFY Preservative Free performs similarly to LUMIFY. The overall safety profile of LUMIFY Preservative Free was favorable and comparable to LUMIFY, and the occurrence of ocular treatment-emergent adverse events was similar in both treatment groups. In this clinical trial, LUMIFY Preservative Free demonstrated to have a low incidence of side effects, like rebound redness and loss of efficacy over time, when used as directed. Article content 'The results show that LUMIFY Preservative Free is a well-tolerated alternative option for consumers with ocular redness who have sensitivities to preservatives or are at increased risk of ocular surface disease,' said Melissa Toyos, MD, and partner, Toyos Clinic, Nashville, TN. Article content About the LUMIFY Brand Article content The LUMIFY brand began in 2018 with the U.S. launch of LUMIFY redness reliever eye drops. Before LUMIFY, redness relievers relied on the same ingredients for decades and were associated with well-known side effects. LUMIFY and LUMIFY Preservative Free are the only over-the-counter redness relievers formulated with low-dose brimonidine tartrate 0.025% that selectively target eye redness and offer excellent results with a lower risk of rebound redness and loss of efficacy when used as directed. In 2023, Bausch + Lomb introduced LUMIFY EYE ILLUMINATIONS™, a line of specialty eye care products specifically developed for the sensitive area around the eyes. In June 2025, Bausch + Lomb launched LUMIFY Preservative Free eye drops in the U.S. For more information on the LUMIFY brand, visit Article content Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit Article content Facebook Article content , Article content Instagram Article content , Article content LinkedIn Article content , Article content X Article content and Article content YouTube Article content . Article content References Article content ©2025 Bausch + Lomb. Article content Article content Article content Article content Article content Article content Contacts Article content Media Contact: Article content Article content Kristy Marks Article content Article content Article content


CTV News
7 hours ago
- CTV News
Early-morning crash slows commute
In this file photo, crews work to repair the guardrail along Highway 400 in Barrie, Ont., after a collision on Thurs., June 12, 2025. A transport truck and pickup truck crashed on Highway 11 southbound at around 4:30 a.m. Tuesday. Ontario Provincial Police spokesperson said the collision occurred just south of Penetanguishene Road and just before the Highway 400 merge. 'A transport truck hit the guard rails,' said the OPP spokesperson. No injuries were reported and all lanes were reopened by 7:30 a.m.


Globe and Mail
7 hours ago
- Globe and Mail
Eli Lilly and Loxo Oncology's Promising Study on Pirtobrutinib for CLL/SLL
(LLY)), Loxo Oncology Inc ((LOXO)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Eli Lilly and Company, in collaboration with Loxo Oncology Inc., is conducting a Phase 3 study titled 'A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)'. The study aims to evaluate the efficacy and safety of the experimental drug Pirtobrutinib compared to the standard treatment of Bendamustine plus Rituximab in patients who have not received prior treatment for CLL/SLL. The study tests two interventions: Pirtobrutinib, an oral medication, and a combination of Bendamustine and Rituximab, administered intravenously. Pirtobrutinib is being evaluated for its potential to offer a more effective and safer treatment option. This interventional study is randomized with a parallel assignment model. Participants are divided equally into two groups, with no masking involved. The primary purpose is treatment, allowing crossover for patients with disease progression. The study began on September 23, 2021, with an active but not recruiting status. The last update was submitted on July 22, 2025, indicating ongoing progress. These dates are crucial for tracking the study's development and anticipated results. The outcome of this study could significantly impact Eli Lilly's and Loxo Oncology's stock performance by potentially introducing a new treatment option in the CLL/SLL market. This could influence investor sentiment positively, especially if Pirtobrutinib proves to be a superior treatment. Competitors in the oncology space will be closely monitoring these developments. The study remains active, with further details available on the ClinicalTrials portal.